Gastrin Hormone Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Gastrin Hormone Market Trends and Insights

Rising Availability of Synthetic Gastrin and Pentagastrin Reagents

The Gastrin hormone market benefits from synthetic supply that is less dependent on biological sourcing. GenScript states that its microwave-assisted PepPower platform achieves a synthesis success rate above 95% and can deliver peptides at 95% purity or higher within 5 business days. Faster synthesis can improve access to research-grade gastrin and pentagastrin for laboratories that require custom peptides. Merck KGaA lists its Sigma-Aldrich Gastrin I product at 95% or higher HPLC purity, showing the continued availability of catalog synthetic material. A 2025 study reported that residual trifluoroacetic acid in synthetic peptides can affect cell-based work when counterion exchange is not performed. These quality considerations can increase demand for materials with validated purity and counterion profiles.

Expansion of Gastrin-17 Testing for Atrophic Gastritis and Helicobacter pylori-Associated Disease

The Gastrin hormone market gains clinical support as Gastrin-17 becomes part of noninvasive gastric risk assessment. The 2025 MAPS III guideline recommends serum pepsinogen I and the pepsinogen I to pepsinogen II ratio for identifying advanced atrophic gastritis that requires endoscopic surveillance. A 2025 BMC Gastroenterology study found that a panel of pepsinogen I, pepsinogen II, pepsinogen ratio, and Gastrin-17 achieved an AUC of 0.759 for progressive atrophic gastritis. Biohit reported that its GastroPanel program in Chile was associated with an 87% reduction in endoscopy waiting lists. Near-patient formats can extend this testing beyond central laboratories when referral pathways support their use. These programs create recurring demand for assay kits, calibrators, and other consumables.

Growing Use of Gastrin in Gastric Organoid and Cancer Research

The Gastrin hormone market also serves academic and biopharmaceutical research through gastric organoid culture. A 2025 Nature Communications study used 10 nM gastrin in primary human 3D gastric tumor organoid media for large-scale CRISPR screening^{[1]Lo, Yuan-Hung, “Large-Scale CRISPR Screening in Primary Human 3D Gastric Organoids Enables Comprehensive Dissection of Gene-Drug Interactions,” Nature Communications, nature.com}. Protocol-based use can make gastrin a recurring research reagent as organoid models are used in drug discovery. This research also supports work on the cholecystokinin-2 receptor, which is a target for receptor-directed radioligands. A 2026 RSC Advances study found that gastramide theranostic compounds GA4 and GA13 extended median survival by 22-23.5 days in AR42J xenograft studies, compared with 6 days for CP04. The Gastrin hormone industry could see further demand for receptor-grade fragments if these programs move beyond preclinical research.

Increasing Referral for Hypergastrinemia and Zollinger-Ellison Syndrome Workups

The Gastrin hormone market is supported by referrals for hypergastrinemia and Zollinger-Ellison syndrome workups. Clinical testing requires patients using proton pump inhibitors to stop treatment before fasting serum gastrin measurement, which can complicate test scheduling. The secretin stimulation test uses serial gastrin measurements and has reported sensitivity of 85-87% for Zollinger-Ellison syndrome at a threshold of 200 pg/mL or higher. A 2025 analysis of 59 ENETS Centers of Excellence found that 98% used fasting serum gastrin, while 55% combined it with gastric pH or provocative testing. Variation in diagnostic practice can lead to repeat testing and continued use of immunoassay reagents. The same care pathway limits routine ordering because testing remains linked to specific clinical questions.

Preanalytical Variability From Fasting, Proton Pump Inhibitor Use, Kidney Failure, and Biotin

Preanalytical variability limits more routine use across the Gastrin hormone market. Proton pump inhibitors elevate fasting serum gastrin by suppressing gastric acid, and patients are generally asked to discontinue them before testing. Biotin can interfere with assays that use streptavidin-biotin technology, which adds another preparation requirement for patients. A Heidelberg laboratory reported in July 2026 that repeated Siemens IMMULITE reagent supply disruptions led it to switch to the Yhlo iFlash Gastrin-17 assay on August 1, 2026. Such disruptions can interrupt laboratory workflows and require revised reference intervals and test procedures. Laboratories need validated collection, storage, and assay procedures to reduce avoidable result variation.

Limited Clinical Translation of CCK2 Receptor Antagonists

The Gastrin hormone market has limited therapeutic demand from CCK2 receptor antagonists because no marketed therapy has yet emerged. Netazepide remains in clinical development for type 1 gastric neuroendocrine tumors, while nastorazepide has been evaluated in pancreatic cancer. A 2026 Theranostics study reported that [177Lu]Lu-DOTAGA-NPP radioligands had 93.1% intact drug at 1 hour, compared with 66.1% for DOTA-MGS5^{[2]Rossi, A., “Novel Nastorazepide-Based Radioligands Demonstrate Effective Cholecystokinin-2 Receptor Targeting With Potential for Theranostic Applications,” Theranostics, thno.org}. The study did not report significant tumor growth inhibition in the xenograft model. This leaves oncology use concentrated in research compounds and preclinical reagent volumes. Cold-chain control, purity assurance, and lot consistency also remain essential for peptide products moving through research and diagnostic workflows.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Gastrin-17 Commands Both Scale and Growth

Gastrin-17 held 34.31% of the Gastrin hormone market share in 2025 and is projected to grow at a CAGR of 8.25% through 2031. Gastrin-17 represents 80-90% of biologically active circulating gastrin, supporting its use in clinical testing and research. The PZ Cormay AURYX 90 Gastrin-17 ECLIA kit has a measuring range of 0.6-500 pmol/L and 56-day onboard stability. These features support use on laboratory platforms that need consistent throughput and reagent stability.

Gastrin-34, minigastrin, and other fragments address more specialized work in neuroendocrine research and tumor biology. Pentagastrin retains a role in gastric acid secretion testing and maximal acid output assessment. Control and reference materials become more important as laboratories use different platforms and measurement units. The July 2026 method change at a German laboratory moved gastrin reporting from ng/L to pmol/L after a platform migration. This transition creates a need for suitable calibrators, controls, and method verification.

By Salt Type: Trifluoroacetate Gains Ground on Emerging Assay Specificity Demands

Ammonium acetate held the largest salt type share at 45.24% in 2025. Acetate-form gastrin remains relevant in cell-based and bioassay applications where residual trifluoroacetic acid can be a concern. A 2025 scientific review discussed the importance of counterion analysis and exchange for synthetic peptides. This supports continued use of salt forms selected for specific assay conditions.

Trifluoroacetate is projected to grow at a CAGR of 8.22% through 2031. Fmoc solid-phase peptide synthesis commonly produces trifluoroacetate-salt peptides, and trifluoroacetic acid is also used in HPLC-based purity work. The 2025 United States Pharmacopeia chapter on trifluoroacetic acid in peptides sets quantification expectations for the substance as an impurity and counterion. This raises quality-control needs for materials supplied for chemistry, manufacturing, and controls work. Other salt types, including acetonitrile and hydrochloride variants, remain specialized formulations.

By Application: Atrophic Gastritis Testing Outpaces All Other Applications

Research reagents and cell signaling held 44.14% of the Gastrin hormone market in 2025. Researchers use gastrin as a culture media supplement, receptor ligand, and probe of secretory pathways. Gastric organoid models embed the reagent in recurring laboratory protocols. A 2025 Nature Communications study illustrates this use through gastrin supplementation in primary human gastric organoid media.

Atrophic gastritis and Helicobacter pylori assessment are projected to grow at a CAGR of 8.42% through 2031. A 2025 analysis estimated that Helicobacter pylori infection was attributable to 76% of expected future gastric cancer cases, representing 15.6 million lifetime cases among people born from 2008-2017. Published 2024 multicenter data from China reported 87.21% sensitivity and 91.86% specificity for combined pepsinogen and Gastrin-17 testing in early gastric cancer screening. Hypergastrinemia and Zollinger-Ellison syndrome workups remain specialized applications, while autoimmune gastritis and achlorhydria assessment support additional demand. The Gastrin hormone industry also serves these clinical applications through assay consumables and reference materials.

By End User: Diagnostic Laboratories Outpace Hospitals in Growth Momentum

Hospitals held 46.14% of the Gastrin hormone market share in 2025. They remain important for complex immunoassay workups, secretin stimulation tests, and inpatient gastroenterology panels. Siemens lists the IMMULITE 2000 XPi among its laboratory immunoassay systems and assay menus. Hospital demand remains tied to specialist care and established testing protocols.

Diagnostic laboratories are projected to grow at a CAGR of 8.12% through 2031. Standalone laboratories can use standardized platforms for higher-volume routine testing. The Yhlo iFlash assay used in the 2026 German laboratory change specifically measures Gastrin-17 at a precision range of 1.5-7.5 pmol/L. Specialty clinics, research institutes, and biopharmaceutical companies add demand through eradication programs, organoid research, and peptide development work. CPC Scientific states that its Rocklin facility can produce more than 1,000 kg of peptide API annually^{[3]CPC Scientific Inc., “CPC Scientific to Showcase Peptide and Oligonucleotide CDMO Leadership at CPHI Frankfurt 2025,” CPC Scientific, cpcscientific.com}.

Geography Analysis

North America held a 35.61% regional share of the Gastrin hormone market in 2025. The United States supports testing through advanced immunoassay infrastructure, gastroenterology services, and specialist endocrinology networks. Thermo Fisher Scientific lists its Human Gastrin ELISA Kit with 9.38 pg/mL sensitivity and an assay range of 15.63-1,000 pg/mL. Canada maintains testing through centralized provincial reference laboratories. Mexico could develop additional testing capacity as population-based Helicobacter pylori screen-and-treat programs are implemented.

Europe ranks second and has varied national approaches to gastrin testing. Germany, the United Kingdom, France, Italy, and Spain support demand through hospitals and specialist laboratories. The MAPS III guideline supports greater consistency in serology-based assessment of atrophic gastritis. In August 2026, MVZ Labor Dr. Limbach changed from Siemens IMMULITE to the Yhlo iFlash Gastrin-17 assay after recurrent reagent supply difficulties. The change shows why laboratories may seek alternatives to single-platform dependence.

Asia-Pacific is projected to record the highest regional CAGR at 8.25% through 2031. China, Japan, India, South Korea, and Australia have substantial Helicobacter pylori and atrophic gastritis testing needs. China published national standard T/GDMDMA 0054-2026 for Gastrin-17 CLIA testing kits in 2026. Japan combines Helicobacter pylori serology and pepsinogen testing within established gastric cancer screening practices. India was a clinical trial site for Biohit GastroPanel Quick Test in 2025, where biopsy-confirmed atrophic gastritis was found in 15.3% of gastroscopy referral patients, and the test achieved an AUC of 0.990 for corpus atrophy. South America, particularly Brazil and Chile, is also building structured gastric biomarker screening programs.